Clinical Trials in North Carolina

Showing 6681-6700 of 20,428 trials

Trial Comparing Peripheral I.V. Catheter Complication Rates of Two Different Catheter Dressings

NCT02725788

A multi-center randomized control trial comparing the dressing wear times of two different transparent film dressings when used to secure peripheral intravenous catheters of hospitalized adult patients.

Surgery

Solventum US LLC247 participantsStarted Sep 2014

Omaha, Nebraska, United States • Chapel Hill, North Carolina, United States • Cleveland, Ohio, United States +2 more locations

COMPLETEDPhase 346 miles

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

NCT01877655

The purpose of the study was to evaluate the efficacy of ASP0113 compared with placebo as measured by a primary composite endpoint of overall mortality and CMV end organ disease (EOD) through 1 year post-transplant. Safety of ASP0113 in participants undergoing allogeneic HCT will also be evaluated.

Cytomegalovirus (CMV)-Positive RecipientsAllogeneic, Hematopoietic Cell Transplant (HCT)

Astellas Pharma Global Development, Inc.514 participantsStarted Sep 2013

Birmingham, Alabama, United States • Tucson, Arizona, United States • San Francisco, California, United States +80 more locations

Trial Comparing Peripheral I.V. Catheter Complication Rates of Two Different Catheter Dressings

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

Find Trials by Condition in North Carolina

Cardiac Resynchronization Therapy Delivery Guided Non-Invasive Electrical and Venous Anatomy Assessment

Embo Registry; National Registry for Artery Embolization

Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma

Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus

Network Interventions to Reduce Disparities in Living Kidney Donation

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

The PRISM Intervention for Adolescents and Young Adults Receiving Hematopoietic Cell Transplantation

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms